Literature DB >> 4813341

Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.

D H Huffman, D W Shoeman, D L Azarnoff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4813341     DOI： 10.1016/0006-2952(74)90410-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  25 in total

1.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.

Authors:  C J van Boxtel; J T Wilson; S Lindgren; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

4.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

Review 5.  Drug pharmacokinetics in the postoperative period.

Authors:  J Elfstrom
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

Review 6.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

7.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

8.  Antipyrine kinetics in liver disease and liver transplantation.

Authors:  M U Mehta; R Venkataramanan; G J Burckart; R J Ptachcinski; S L Yang; J A Gray; D H Van Thiel; T E Starzl
Journal:  Clin Pharmacol Ther       Date:  1986-04       Impact factor: 6.875

Review 9.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

10.  Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity.

Authors:  T A Moreland; B K Park; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.